GNCA Genocea Biosciences Inc

Price (delayed)

$2.23

Market cap

$121.39M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.87

Enterprise value

$74.37M

Sector: Healthcare
Industry: Biotechnology

Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or ...

Highlights

The quick ratio has surged by 81% since the previous quarter
GNCA's EPS is up by 39% YoY and by 11% QoQ
Genocea Biosciences's equity has shrunk by 86% YoY and by 80% QoQ
The company's net income fell by 18% YoY

Key stats

What are the main financial stats of GNCA
Market
Shares outstanding
54.43M
Market cap
$121.39M
Enterprise value
$74.37M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
67.73
Price to sales (P/S)
108.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
54.72
Earnings
Revenue
$1.36M
EBIT
-$41.44M
EBITDA
-$40.2M
Free cash flow
-$43.63M
Per share
EPS
-$0.87
Free cash flow per share
-$0.66
Book value per share
$0.03
Revenue per share
$0.02
TBVPS
$1.27
Balance sheet
Total assets
$83.94M
Total liabilities
$82.18M
Debt
$19.64M
Equity
$1.76M
Working capital
$57.4M
Liquidity
Debt to equity
11.15
Current ratio
6.02
Quick ratio
5.84
Net debt/EBITDA
1.17
Margins
EBITDA margin
-2,958.1%
Gross margin
100%
Net margin
-3,152.6%
Operating margin
-3,387.5%
Efficiency
Return on assets
-52.1%
Return on equity
-439.6%
Return on invested capital
-200.3%
Return on capital employed
-57.2%
Return on sales
-3,049.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

GNCA stock price

How has the Genocea Biosciences stock price performed over time
Intraday
1.83%
1 week
-3.46%
1 month
0.9%
1 year
-11.86%
YTD
-7.85%
QTD
-17.71%

Financial performance

How have Genocea Biosciences's revenue and profit performed over time
Revenue
$1.36M
Gross profit
$1.36M
Operating income
-$46.04M
Net income
-$42.84M
Gross margin
100%
Net margin
-3,152.6%
The company's net income fell by 18% YoY
The operating income has contracted by 7% YoY but it has grown by 2% from the previous quarter
The company's operating margin rose by 2% QoQ

Growth

What is Genocea Biosciences's growth rate over time

Valuation

What is Genocea Biosciences stock price valuation
P/E
N/A
P/B
67.73
P/S
108.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
54.72
GNCA's EPS is up by 39% YoY and by 11% QoQ
The stock's P/B is 152% above its last 4 quarters average of 26.9
Genocea Biosciences's equity has shrunk by 86% YoY and by 80% QoQ
GNCA's P/S is 15% above its last 4 quarters average of 94.6

Efficiency

How efficient is Genocea Biosciences business performance
The ROIC has contracted by 38% YoY
Genocea Biosciences's ROE has decreased by 26% from the previous quarter
The ROA has grown by 18% YoY and by 13% from the previous quarter
GNCA's ROS is up by 2.1% QoQ

Dividends

What is GNCA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GNCA.

Financial health

How did Genocea Biosciences financials performed over time
Genocea Biosciences's total assets is 2.1% more than its total liabilities
The company's total liabilities has surged by 155% YoY but it fell by 8% QoQ
Genocea Biosciences's total assets has soared by 86% YoY but it has decreased by 15% from the previous quarter
Genocea Biosciences's equity has shrunk by 86% YoY and by 80% QoQ
Genocea Biosciences's debt has decreased by 23% YoY and by 18% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.